PMCPA Case
| Case number | AUTH/2996/12/17 |
| Complainant | CCG lead prescribing support pharmacist |
| Company | Seqirus UK Limited |
| Product | Fluad (influenza vaccine, adjuvanted) |
| Material | Promotional email (ref UK/FLUD/0917/0026c) |
| Date sent | 11 December 2017 |
| Core allegation | Email misleadingly implied JCVI changed recommendations so Fluad should be used for everyone over 65; misleading cost-effectiveness/budget impact; most cost-effective in over 75s |
| Authority clauses considered | 7.2, 7.3, 7.4, 9.1, 10.2 |
| Outcome | No breach |
| Complaint received | 14 December 2017 |
| Case completed | 10 May 2018 |
| Applicable Code year | 2016 |
| Appeal | No appeal |
Download the full case report (PDF)
Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory
Got a question about this case?
Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.
⭐ Business Intelligence Access
See the full compliance picture for every pharma company
291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.
One real case. One key lesson. Every week — free.